Theradiag, a French company that specializes in in vitro diagnostics and theranostics, has entered into a partnership agreement with Biogen to provide its Lisa Tracker kits to monitor patients treated with Biogen’s infliximab biosimilar Flixabi, which was approved in Europe in 2016.
Theradiag, a French company that specializes in in vitro diagnostics and theranostics (targeted therapy based on targeted diagnostic tests), has entered into a partnership agreement with Biogen to provide its Lisa Tracker kits to monitor patients treated with Biogen’s infliximab biosimilar Flixabi, which was approved in Europe in 2016.
The partnership will allow Biogen to supply Lisa Tracker monitoring kits in France and other European countries to optimize the treatment of patients receiving the biosimilar. Flixabi is indicated for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriasis, and psoriatic arthritis. Under the agreement, Theradiag will be Biogen’s preferred supplier of infliximab monitoring kits. Theradiag will also handle implementation, provide training to laboratories in how to use the kits, and follow up on clinician requests concerning monitoring.
Lisa Tracker kits are used to monitor patients taking biotherapies for diseases ranging from gastroenterology, rheumatology, and dermatology to oncology. The kits allow clinicians to simultaneously monitor patients’ trough plasma levels of 3 parameters within 3 hours of reaction from a serum sample in order to anticipate, optimize, and better manage patients’ treatment with infliximab:
Consensus statements support therapeutic drug monitoring (TDM) used to guide and optimize anti-TNF therapy in IBD, particularly in situations of treatment failure. One such statement, issued by the Australian Inflammatory Bowel Disease Consensus Working Group and other international experts, recommended TDM of anti-TNF agents upon treatment failure, following successful treatment induction, and when contemplating a drug holiday.
However, the group said there is inconsistent evidence for proactive TDM, and therefore advised that TDM should be performed for patients in stable remission only if results are likely to impact clinical management.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Trastuzumab-dkst Shows Promising Results in Real-World Setting for HER2+ Breast Cancer
July 9th 2024A Brazilian real-world study found trastuzumab-dkst to be an effective and safe adjuvant therapy for HER2-positive (HER2+) breast cancer, with clinical outcomes comparable to reference trastuzumab.